Strategy for randomised clinical trials in rare cancers

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British medical journal

• Publication date

  2003-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bmj.327.7405.47PMID 12842959PMCID PMC1126386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.

  2003cited by this paper
• Following a trial that stopped early: what next for adjuvant hepatic intra-arterial iodine-131 lipiodol in resectable hepatocellular carcinoma?

  2002cited by this paper
• Underpowered studies.

  2002cited by this paper
• Underpowered studies

  2002cited by this paper
• Monitoring of large randomised clinical trials: a new approach with Bayesian methods.

  2001cited by this paper
• On the use of surrogate end points in randomized trials

  2000cited by this paper
• An introduction to bayesian methods in health technology assessment

  1999cited by this paper
• Why "underpowered" trials are not necessarily unethical.

  1997cited by this paper
• Surrogate End Points in Clinical Trials: Are We Being Misled?

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Clinical trials and rare diseases: a way out of a conundrum

  1995cited by this paper
• The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee.

  1994cited by this paper
• The what, why and how of Bayesian clinical trials monitoring.

  1994cited by this paper
• Discussion of ‘the what, why and how of bayesian clinical trials monitoring’

  1994cited by this paper
• Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991.

  1993cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper

• Medical decision analysis for personalized oncology at the patient bedside

  2026cites this paper
• Empowering pediatric, adolescent, and young adult patients with cancer utilizing generative AI chatbots to reduce psychological burden and enhance treatment engagement: a pilot study

  2025cites this paper
• An Evaluation of Rare Cancer Policies in Europe: A Survey Among Healthcare Providers

  2025cites this paper
• Navigating the uncommon: challenges in applying evidence-based medicine to rare diseases and the prospects of artificial intelligence solutions

  2024cites this paper
• Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures

  2024cites this paper
• Improving the efficiency of clinical trials in multiple sclerosis

  2023cites this paper
• Challenging gestational trophoblastic disease cases and mimics: An exemplar for the management of rare tumours.

  2023cites this paper
• Primary Small Cell Carcinoma of the Breast: When a Rare Tumour is Real

  2023cites this paper
• Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach.

  2022cites this paper
• Association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study

  2022cites this paper
• Descriptive Epidemiology of Hospitalization of Patients with a Rare Tumor in an Italian Region

  2022cites this paper
• Elbow arthroplasty research methods, outcome domains, and instruments used in clinical outcome studies : a scoping review.

  2022cites this paper
• Error in Title.

  2022cites this paper
• Descriptive epidemiological study of rare, less common and common cancers in Western Australia

  2021cites this paper
• Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers

  2021cites this paper
• Clinical and Translational research challenges in Neuroendocrine Tumours.

  2020cites this paper
• Effi cacy in Treating Rare Pediatric Tumors : Introduction to European Regulatory and Scientifi c Support Available to Investigators

  2019cites this paper
• Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study

  2019cites this paper
• A quantitative framework to inform extrapolation decisions in children

  2019cites this paper
• Approche Bayésienne de la survie dans les essais cliniques pour les cancers rares

  2018cites this paper
• Bridging the gap:using extrapolation to reduce the experimental burden in children

  2018cites this paper
• Clinical trial methodology in rare gynecologic tumor research: Strategies for success.

  2018cites this paper
• How a Clinical Trial Unit can improve independent clinical research in rare tumors: the Italian Sarcoma Group experience

  2017cites this paper
• University of Birmingham Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers

  2017cites this paper
• Emerging Opportunities for Target Discovery in Rare Cancers.

  2017cites this paper
• Evidence-Based Medicine and Rare Diseases.

  2017cites this paper
• Rare cancers: Challenges & issues

  2017cites this paper
• Drug development challenges and strategies to address emerging and resistant fungal pathogens

  2017cites this paper
• Appendix C: Areas Under The Standard Normal Curve

  2017cites this paper
• Bayesian survival analysis in clinical trials: What methods are used in practice?

  2017cites this paper
• Méthodes d'aide à la décision thérapeutique dans les cas des maladies rares : intérêt des méthodes bayésiennes et application à la maladie de Horton

  2017cites this paper
• Alternative designs for clinical trials in rare diseases

  2016cites this paper
• Research methods to change clinical practice for patients with rare cancers.

  2016cites this paper
• New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study

  2016cites this paper
• Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing’s sarcoma

  2016cites this paper
• Good-quality research in rare diseases: trials and tribulations

  2016cites this paper
• Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

  2016cites this paper
• On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma.

  2015influential citation
• Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

  2015cites this paper
• Bridging the gap: a review of dose investigations in paediatric investigation plans

  2014cites this paper
• The End-of-Life Experience of Patients With Rare Cancers and Their Caregivers

  2014cites this paper
• Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion

  2014cites this paper
• Bayesian methods for the design and interpretation of clinical trials in very rare diseases

  2014cites this paper
• Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper

  2014cites this paper
• Innovative research methods for studying treatments for rare diseases: methodological review

  2014cites this paper
• Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses.

  2013cites this paper
• Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas

  2013cites this paper
• An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour.

  2013cites this paper
• Drainage as the Initial Surgical Therapy for ELBW Infants with Necrotizing Enterocolitis ( NEe ) or Isolated Intestinal Perforation ( IP ) : Outcomes at 18-22 months Adjusted Age . Short Title : Necrotizing Enterocolitis Surgery Trial ( NEST )

  2013cites this paper
• Design of studies for medical research

  2013influential citation
• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

  2013cites this paper
• recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in adults

  2013cites this paper
• A Multi-center Randomized Trial of Laparotomy vs. Drainage as the Initial Surgical Therapy for ELBW Infants with Necrotizing Enterocolitis (NEC) or Isolated Intestinal Perforation (IP): Outcomes at 18-22 months Adjusted Age. Short Title: Necrotizing Enterocolitis Surgery Trial (NEST)

  2013cites this paper
• adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in

  2013cites this paper
• International rare cancers initiative.

  2013cites this paper
• Showing Efficacy in Treating Rare Pediatric Tumors: Introduction to European Regulatory and Scientific Support Available to Investigators

  2012cites this paper
• Small sample sizes in clinical trials: a statistician's perspective

  2012cites this paper
• Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme

  2012cites this paper
• Looking ahead: clinical trial design in adult congenital heart disease.

  2012cites this paper
• MOLECULAR CHARACTERIZATION OF MUCINOUS OVARIAN TUMORS SUPPORTS A STRATIFIED TREATMENT APPROACH WITH HER2 TARGETING IN 18% OF CARCINOMAS.

  2012cites this paper
• mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis

  2011cites this paper
• Strategies for Trial Design and Analyses

  2011cites this paper
• A framework for applying unfamiliar trial designs in studies of rare diseases.

  2011cites this paper
• Trials in rare diseases: the need to think differently

  2011cites this paper
• Rare cancers are not so rare: the rare cancer burden in Europe.

  2011cites this paper
• Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency.

  2010cites this paper
• Phase II Clinical Trials

  2010cites this paper
• Evidence-based medicine and rare diseases.

  2010cites this paper
• Do rare cancers deserve specific strategies for cancer research?

  2010cites this paper
• Trialing plasma protein therapies for rare disorders: Thinking outside the box

  2009cites this paper
• Pseudoxanthoma elasticum: genetics, clinical manifestations and therapeutic approaches.

  2009cites this paper
• Application of Decision-Analytic Modelling in Health Economic Evaluations

  2008cites this paper
• Web‐based international studies in limited populations of pediatric leukemia

  2008cites this paper
• Can external and subjective information ever be used to reduce the size of randomised controlled trials?

  2008cites this paper
• Improving recruitment to clinical trials for cancer in childhood.

  2008cites this paper
• Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.

  2007cites this paper
• Surgical and oncology trials for rectal cancer: who will participate?

  2007cites this paper
• A survey of physician's attitudes regarding management of severe group A streptococcal infections

  2006cites this paper
• Specific Issues in Relation to Clinical Trials

  2006cites this paper
• Issues in the design and analysis of clinical trials with time-to-event outcomes.

  2006cites this paper
• Prior distributions for the intracluster correlation coefficient, based on multiple previous estimates, and their application in cluster randomized trials

  2005cites this paper
• Anti‐Hip Fracture Efficacy of Bisphosphonates: A Bayesian Analysis of Clinical Trials

  2005cites this paper
• COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON CLINICAL TRIALS IN SMALL POPULATIONS

  2005cites this paper
• Widening eligibility to phase II trials: constant arcsine difference phase II trials.

  2004cites this paper
• On the evolution of statistical methods as applied to clinical trials

  2004cites this paper
• Ocular oncology and the study of rare cancers.

  2004cites this paper
• References

  year unknowncites this paper